Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith S Reisinger

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Clinical Pediatrics|May 10, 2008
Characteristics of an ideal rotavirus vaccineKeith S Reisinger, Stan L Block
Clinical Pediatrics|January 22, 2010
Optimizing protection against meningococcal diseaseKeith S Reisinger, Steven Black, Jeffrey J Stoddard
Antimicrobial Agents and Chemotherapy|August 29, 2007
Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjectsStan L Block, Keith S Reisinger, Micki Hultquist, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccinationKeith S Reisinger, Sandra J Holmes, Paola Pedotti, et al.
The Journal of Infectious Diseases|August 14, 2009
Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicityKeith S Reisinger, Stanley L Block, Allen Izu, et al.
Clinical and Vaccine Immunology : CVI|October 9, 2009
Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, MenactraKeith S Reisinger, Roger Baxter, Stanley L Block, et al.
The Pediatric Infectious Disease Journal|November 19, 2011
Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infantsNicola P Klein, Keith S Reisinger, William Johnston, et al.
The Pediatric Infectious Disease Journal|January 1, 2009
A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescentsLisa A Jackson, Robert M Jacobson, Keith S Reisinger, et al.
Clinical Pediatrics|March 26, 2011
Lactose-free milk protein-based infant formula: impact on growth and gastrointestinal tolerance in infantsJohn B Lasekan, Joan Jacobs, Keith S Reisinger, et al.
Vaccine|August 28, 2018
A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX®Keith S Reisinger, Elizabeth Richardson, Edgardo A Malacaman, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Clinical Pediatrics|May 10, 2008
Characteristics of an ideal rotavirus vaccineKeith S Reisinger, Stan L Block
Clinical Pediatrics|January 22, 2010
Optimizing protection against meningococcal diseaseKeith S Reisinger, Steven Black, Jeffrey J Stoddard
Antimicrobial Agents and Chemotherapy|August 29, 2007
Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjectsStan L Block, Keith S Reisinger, Micki Hultquist, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccinationKeith S Reisinger, Sandra J Holmes, Paola Pedotti, et al.
The Journal of Infectious Diseases|August 14, 2009
Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicityKeith S Reisinger, Stanley L Block, Allen Izu, et al.
Clinical and Vaccine Immunology : CVI|October 9, 2009
Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, MenactraKeith S Reisinger, Roger Baxter, Stanley L Block, et al.
The Pediatric Infectious Disease Journal|November 19, 2011
Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infantsNicola P Klein, Keith S Reisinger, William Johnston, et al.
The Pediatric Infectious Disease Journal|January 1, 2009
A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescentsLisa A Jackson, Robert M Jacobson, Keith S Reisinger, et al.
Clinical Pediatrics|March 26, 2011
Lactose-free milk protein-based infant formula: impact on growth and gastrointestinal tolerance in infantsJohn B Lasekan, Joan Jacobs, Keith S Reisinger, et al.
Vaccine|August 28, 2018
A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX®Keith S Reisinger, Elizabeth Richardson, Edgardo A Malacaman, et al.
Pageof 3